correct, these were the first ever results. No other drug has ever been tested in this indication. if not for the 3 F6 patients the title of the PR would have read " Phase 2b Primary endpoint met". People are only looking at the headline and not the entire picture. That's where you take advantage. I can't believe all this selling. they were the first to prove anti-fibrotic effect with emricasan in this patient population. I see Novartis as pressing on to a phase 3 study for sure. F3 through F5 was 95% response (19 out of 20) patients in a severely sick population. No other drug does that, and it's safe. Novartis will push this to a phase 3 for sure.
News 
Market Data 
Discover 
